Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP - Results from the German competence network CAPNETZ

Respiratory Research

Volumn 10, Issue , 2009, Pages

  Krüger, Stefan ^a   Ewig, Santiago ^b   Papassotiriou, Jana ^c   Kunde, Jan ^c   Marre, Reinhard ^d   von Baum, Heike ^d   Suttor, Norbert ^e   Welte, Tobias ^f  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b Augusta Kranken Anstalt   (Germany)

^c THERMO FISHER SCIENTIFIC   (Germany)

^d UNIVERSITY HOSPITAL ULM   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; PROCALCITONIN; BIOLOGICAL MARKER; CALCITONIN; PROTEIN PRECURSOR;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; BACTERIAL VIRULENCE; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HOSPITALIZATION; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL PARAMETERS; OUTPATIENT; PNEUMONIA; PREDICTION; PROTEIN BLOOD LEVEL; VIRUS INFECTION; VIRUS VIRULENCE; ADOLESCENT; BACTERIAL PNEUMONIA; BLOOD; COMMUNICABLE DISEASE; GERMANY; INFLAMMATION; METABOLISM; MICROBIOLOGY; MIDDLE AGED; PATHOLOGY; ROC CURVE; VIROLOGY; VIRUS PNEUMONIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CALCITONIN; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; GERMANY; HUMANS; INFLAMMATION; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PNEUMONIA; PNEUMONIA, BACTERIAL; PNEUMONIA, VIRAL; PROTEIN PRECURSORS; ROC CURVE; YOUNG ADULT;

EID: 70249096300     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-10-65     Document Type: Article

References (37)

1. Korppi M, Heiskanen-Kosma T, Leinonen M. White blood cells, C-reactive protein, and erythrocyte sedimentation rate in pneumococcal pneumonia in children. Eur Respir J 1997, 10:1125-1129. 10.1183/09031936.97.10051125, 9163657.
2. Heiskanen-Kosma T, Korppi M. Serum C-reactive protein cannot differentiate bacterial and viral aetiology of community-acquired pneumonia in children in primary healthcare settings. Scand J Infect Dis 2000, 32:399-402. 10.1080/003655400750044971, 10959648.
3. Clyne B, Olshaker JS. The C-reactive protein. J Emerg Med 1999, 17:1019-1025. 10.1016/S0736-4679(99)00135-3, 10595891.
4. Boussekey N, Leroy O, Alfandari S, Devos P, Georges H, Guery B. Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia. Intensive Care Med 2006, 32:469-472. 10.1007/s00134-005-0047-8, 16477418.
5. Boussekey N, Leroy O, Georges H, Devos P, d'Escrivan T, Guery B. Diagnostic and prognostic values of admission procalcitonin levels in community-acquired pneumonia in an intensive care unit. Infection 2005, 33:257-263. 10.1007/s15010-005-4096-2, 16091896.
6. Brunkhorst FM, Al-Nawas B, Krummenauer F, Forycki ZF, Shah PM. Procalcitonin, C-reactive protein and APACHE II score for risk evaluation in patients with severe pneumonia. Clin Microbiol Infect 2002, 8:93-100. 10.1046/j.1469-0691.2002.00349.x, 11952722.
7. Harbarth S, Holeckova K, Froidevaux C, Pittet D, Ricou B, Grau GE, Vadas L, Pugin J, . Geneva Sepsis Network Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 2001, 164:396-402. Geneva Sepsis Network.
8. Hausfater P, Garric S, Ayed SB, Rosenheim M, Bernard M, Riou B. Usefulness of procalcitonin as a marker of systemic infection in emergency department patients: a prospective study. Clin Infect Dis 2002, 34:895-901. 10.1086/339198, 11880953.
9. Oppert M, Reinicke A, Muller C, Barckow D, Frei U, Eckardt KU. Elevations in procalcitonin but not C-reactive protein are associated with pneumonia after cardiopulmonary resuscitation. Resuscitation 2002, 53:167-170. 10.1016/S0300-9572(02)00008-4, 12009220.
10. Hedlund J, Hansson LO. Procalcitonin and C-reactive protein levels in community-acquired pneumonia: correlation with etiology and prognosis. Infection 2000, 28:68-73. 10.1007/s150100050049, 10782390.
11. Masia M, Gutierrez F, Shum C, Padilla S, Navarro JC, Flores E, Hernandez I. Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index. Chest 2005, 128:2223-2229. 10.1378/chest.128.4.2223, 16236878.
12. Krüger S, Ewig S, Marre R, Papassotiriou J, Richter K, von Baum H, Suttorp N, Welte T. Procalcitonin predicts patients at low risk of death from community- acquired pneumonia. Eur Resp J 2008, 31:349-355.
13. Welte T, Suttorp N, Marre R. CAPNETZ-community-acquired pneumonia competence network. Infection 2004, 32:234-238. 10.1007/s15010-004-3107-z, 15293080.
14. Neill AM, Martin IR, Weir R, Anderson R, Chereshsky A, Epton MJ, Jackson R, Schousboe M, Frampton C, Hutton S, Chambers ST, Town GI. Community acquired pneumonia: aetiology and usefulness of severity criteria on admission. Thorax 1996, 51:1010-1016. 472650, 8977602, 10.1136/thx.51.10.1010.
15. Lim WS, Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, Lewis SA, Macfarlane JT. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003, 58:377-382. 1746657, 12728155, 10.1136/thorax.58.5.377.
16. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997, 336:243-250. 10.1056/NEJM199701233360402, 8995086.
17. Buising KL, Thursky KA, Black JF, MacGregor L, Street AC, Kennedy MP, Brown GV. A prospective comparison of severity scores for community acquired pneumonia: reconsidering what is meant by severe pneumonia. Thorax 2006, 61:419-424. 2111174, 16449258, 10.1136/thx.2005.051326.
18. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine MJ, Gross PA, Martinez F, Marrie TJ, Plouffe JF, Ramirez J, Sarosi GA, Torres A, Wilson R, Yu VL, . American Thoracic Society Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001, 163:1730-1754. American Thoracic Society.
19. Bauer TT, Ewig S, Marre R, Suttorp N, Welte T, . The Capnetz Study Group CRB-65 predicts death from community-acquired pneumonia. J Intern Med 2006, 260:93-101. 10.1111/j.1365-2796.2006.01657.x, 16789984, The Capnetz Study Group.
20. Niederman MS, Feldmann C, Richards GA. Combining information from prognostic scoring tools for CAP: an American view on how to get the best of all worlds. Eur Respir J 2006, 27:9-11. 10.1183/09031936.06.00130305, 16387929.
21. Polzin A, Pletz M, Erbes R, Raffenberg M, Mauch H, Wagner S, Arndt G, Lode H. Procalcitonin as a diagnostic tool in lower respiratory tract infections and tuberculosis. Eur Respir J 2003, 21:939-943. 10.1183/09031936.03.00055103, 12797485.
22. Oosterheert JJ, Bonten MJ, Hak E, Schneider MM, Hoepelman AI. Severe community-acquired pneumonia: what's in a name?. Curr Opin Infect Dis 2003, 16:153-159.
23. Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, Muller B. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004, 363:600-607. 10.1016/S0140-6736(04)15591-8, 14987884.
24. Christ-Crain M, Stolz D, Bingisser R, Muller C, Miedinger D, Huber PR, Zimmerli W, Harbarth S, Tamm M, Muller B. Procalcitonin-Guidance of Antibiotic Therapy in Community-Acquired Pneumonia - A Randomized Trial. Am J Respir Crit Care Med 2006, 174:84-93. 10.1164/rccm.200512-1922OC, 16603606.
25. Toikka P, Irjala K, Juvén T, Virkki R, Mertsola J, Leinonen M, Ruuskanen O. Serum procalcitonin, C-reactive protein and interleukin-6 for distinguishing bacterial and viral pneumonia in children. Pediatr Infect Dis J 2000, 19:598-602. 10.1097/00006454-200007000-00003, 10917215.
26. Korppi M, Remes S, Heiskanen-Kosma T. Serum procalcitonin concentrations in bacterial pneumonia in children: a negative result in primary healthcare settings. Pediatr Pulmonol 2003, 35:56-61. 10.1002/ppul.10201, 12461740.
27. Tillett WS, Francis T. Serological reactions in pneumonia with non-protein somatic fraction of pneumococcus. J Exp Med 1930, 52:561-571.
28. Smith RP, Lipworth BJ, Cree IA, Spiers EM, Winter JH. C-reactive protein. A clinical marker in community-acquired pneumonia. Chest 1995, 108:1288-1291. 10.1378/chest.108.5.1288, 7587431.
29. Ortqvist A, Hedlund J, Wretlind B, Carlstrom A, Kalin M. Diagnostic and prognostic value of interleukin-6 and C-reactive protein in community-acquired pneumonia. Scand J Infect Dis 1995, 27:457-462. 10.3109/00365549509047046, 8588135.
30. Garcia Vazquez E, Martinez JA, Mensa J, Sanchez F, Marcos MA, de Roux A, Torres A. C-reactive protein levels in community-acquired pneumonia. Eur Respir J 2003, 21:702-705. 10.1183/09031936.03.00080203, 12762360.
31. Moulin F, Raymond J, Lorrot M, Marc E, Coste J, Iniguez JL, Kalifa G, Bohuon C, Gendrel D. Procalcitonin in children admitted to hospital with community acquired pneumonia. Arch Dis Child 2001, 84:332-336. 1718706, 11259234, 10.1136/adc.84.4.332.
32. Almirall J, Bolíbar I, Toran P, Pera G, Boquet X, Balanzó X, Sauca G, . Community-Acquired Pneumonia Maresme Study Group Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest 2004, 125:1335-1342. 10.1378/chest.125.4.1335, 15078743, Community-Acquired Pneumonia Maresme Study Group.
33. Ortqvist A, Hedlund J, Grillner L, Jalonen E, Kallings I, Leinonen M, Kalin M. Aetiology, outcome and prognostic factors in patients with community-acquired pneumonia requiring hospitalization. Eur Respir J 1990, 3:1105-1113.
34. Bohte R, van Furth R, Broek PJ. Aetiology of community-acquired pneumonia: a prospective study among adults requiring admission to hospital. Thorax 1995, 50:543-547. 1021226, 7597669, 10.1136/thx.50.5.543.
35. Fang GD, Fine M, Orloff J, Arisumi D, Yu VL, Kapoor W, Grayston JT, Wang SP, Kohler R, Muder RR, et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases. Medicine 1990, 69:307-316. 10.1097/00005792-199009000-00004, 2205784.
36. Farr BM, Kaiser DL, Harrison BDW, Connolly C. Prediction of microbial aetiology at admission to hospital for pneumonia from the presenting clinical features. Thorax 1989, 44:1031-1035. 1020880, 2515602, 10.1136/thx.44.12.1031.
37. Ewig S, Torres A, Angeles Marcos M, Angrill J, Rañó A, de Roux A, Mensa J, Martínez JA, de la Bellacasa JP, Bauer T. Factors associated with unknown aetiology in patients with community-acquired pneumonia. Eur Respir J 2002, 20:1254-1262. 10.1183/09031936.02.01942001, 12449182.